November 27th 2024
LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.
November 25th 2024
November 15th 2024
November 14th 2024
November 12th 2024
Simplifying CAR T-Cell Manufacturing for R/R B-Cell Non-Hodgkin’s Lymphoma
May 19th 2022Manali Kamdar, MD, MBBS, discusses the background on a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell non-Hodgkin’s lymphoma.
Watch
Stem Cell Transplant Holds its Position as Upfront Treatment for Hematologic Malignancies
May 10th 2022In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed the evolving role of stem cell transplant in hematologic malignancies as CAR T-cell therapies begin to reshape treatment landscapes.
Read More
Next Generation Treatments for Blood Cancers: Improved Outcomes in the Forecast
May 9th 2022As these new techniques evolve and we adjust conditioning regimens, induction timing and dosing levels, as well as introducing different drug combinations, we are very hopeful that we will continue to see improved outcomes for hematologic malignancies, says Guenther Koehne, MD, PhD.
Read More
Early Research on Targeting the Sugar Coat of Tumors Cells Expands to Hematologic Malignancies
May 5th 2022In an interview with Targeted Oncology, Robert Sackstein, MD, discussed ongoing research around the strategy of targeting the sugar coat of cancer cells to potentially aid in cancer treatment, particularly in hematologic malignancies.
Read More
Acute GVHD Responds Quickly to Itolizumab Treatment in Phase 1b Trial
May 3rd 2022The positive results from EQUTE informed the doses that will be evaluated in the phase 3 EQUATOR trial of tolizumab versus placebo in combination with corticosteroids as a first-line treatment in patients with acute graft-versus-host disease.
Read More
GVHD Prophylaxis After TBI Decreases Rates of GVHD in Hematologic Malignancies
April 25th 2022Total body irradiation (TBI) regimen and myeloablative transplantation followed by a graft-versus-host disease (GVHD) prophylaxis regimen resulted in a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies
Read More
Envisioning a Path Forward for PI3K inhibitors in Hematologic Malignancies
April 25th 2022In an interview with Targeted Oncology, Basem Goueli, MD, PhD, MBA, discussed the recent crackdown on PI3K inhibitors and how this drug class may fit into future treatment for hematologic malignancies as well as solid tumors.
Read More
FDA’s ODAC Votes Yes to Requiring Randomized Data for Future PI3Ki Approvals in Hematologic Cancers
April 21st 2022In a 16 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee has voted yes to future approvals of PI3K inhibitors being supported by randomized data given observed toxicities in the drug class, research showing a detriment in OS, a narrow range between effective, and toxic doses.
Read More
Non-Response to Blinatumomab Shows Significant Association With Worse Survival Outcomes in B-ALL
April 6th 2022In pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia who had a non-response to blinatumomab and a high-disease burden, worse outcomes were observed , according to retrospective research.
Read More